Effects of circulating member B of the family with sequence similarity 3 on the risk of developing metabolic syndrome and its components: A 5‐year prospective study. Issue 4 (3rd January 2018)

• Record Type: Journal Article
• Authors: Wang, Haoyu; Yu, Fadong; Zhang, Zhuo; Hou, Yuanyuan; Teng, Weiping; Shan, Zhongyan; Lai, Yaxin
• Is Part Of: Journal of diabetes investigation. Volume 9:Issue 4(2018)
• Page Start: 782
• Page End: 788
• Publication Date: 2018-01-03
• Subjects: Member B of the family with sequence similarity 3 -- Metabolic syndrome -- Prospective study; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12780
• Languages: English
• ISSNs: 2040-1116

Abstract

Abstract: Aims/Introduction: Member B of the family with sequence similarity 3 (FAM3B), also known as pancreatic‐derived factor, is mainly synthesized and secreted by islet β‐cells, and plays a role in abnormal metabolism of glucose and lipids. However, the prospective association of FAM3B with metabolic disorders remains unclear. The present study aimed to reveal the predictive relationship between pancreas‐specific cytokine and metabolic syndrome (MetS). Materials and Methods: A total of 210 adults (88 men and 122 women) without MetS, aged between 40 and 65 years, were recruited and received a comprehensive health examination. Baseline serum FAM3B levels were determined by sandwich enzyme‐linked immunosorbent assay. Subsequently, all participants underwent a follow‐up examination after 5 years. MetS was identified in accordance with the International Diabetes Federation criteria. Results: During follow up, 35.7% participants developed MetS. In comparison with the non‐MetS group, participants with MetS had an increased serum FAM3B at baseline (21.85 ng/mL [19.38, 24.17 ng/mL] vs 28.56 ng/mL [25.32, 38.10 ng/mL], P < 0.001). Moreover, serum FAM3B was significantly associated with variations in fasting plasma insulin ( r = −0.306, P < 0.001), homeostasis model assessment of β‐cell function ( r = −0.328, P < 0.001) and homeostasis model assessment of insulin resistance ( r = −0.191, P = 0.006). Furthermore, a positive correlation between baseline FAM3B and the incidence of MetS was observed, even after multivariable adjustment (relative risk 1.23 [1.15, 1.31], P < 0.001). Furthermore, the optimal cut‐off values of FAM3B was 23.98 ng/mL for predicting MetS based on the Youden Index. Conclusions: Elevated circulating FAM3B might be considered as a predictor of newly‐onset MetS and its progression. Abstract : Our study is the first report to evaluate the prospective association between of FAM3B with glucose and lipid metabolism in adults. We indicated that circulating FAM3B levels maybe a predictor of metabolic syndrome.